Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

388 Views

Poster Session: COVID-19: Treatment

1123 - EDP-235, A Potent and Once-daily Oral Antiviral, Demonstrates Excellent Penetration into Macrophages and Monocytes, with the Potential for Mitigation of Cytokine Storm in High-Risk COVID-19 Patients

Friday, October 21, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Co-Author(s)

YL

Yang Li, Ph. D

Scientist
Enanta Pharmaceuticals, Inc.
Watertown, MA, United States
TZ

Tianzhu Indy Zang, Ph. D.

Enanta Pharmaceuticals, Inc.
Watertown, Massachusetts, United States
LX

Lisha Xu, B. Sc

Scientist
Enanta Pharmaceuticals, Inc.
Watertown, MA, United States
DL

Daniel Leonard, B. Sc.

Enanta Pharmaceuticals, Inc.
Watertown, Massachusetts, United States
KH

Khanh Hoang, B. Sc.

Enanta Pharmaceuticals, Inc.
Watertown, Massachusetts, United States
TG

Tim Greizer, B. Sc.

Enanta Pharmaceuticals, Inc.
Watertown, Massachusetts, United States
SZ

Shucha Zhang, Ph. D

Scientist
Enanta Pharmaceuticals, Inc.
Watertown, MA, United States
CF

Caroline Foster, B. Sc.

Enanta Pharmaceuticals, Inc.
Watertown, Massachusetts, United States
MH

Meng Huang, Ph. D

Scientist
Enanta Pharmaceuticals, Inc.
Watertown, MA, United States
JK

Jonathan Kibel, B. Sc

Research Associate
Enanta Pharmaceuticals, Inc.
Watertown, MA, United States
JK

Joshua Klaene, Ph. D.

Enanta Pharmaceuticals, Inc.
Watertown, Massachusetts, United States
YO

Yat Sun Or, Ph. D

CSO
Enanta Pharmaceuticals, Inc.
Watertown, MA, United States

Presenting Author(s)

Li-Juan Jiang, Ph. D

Vice President
Enanta Pharmaceuticals, Inc.
Watertown, Massachusetts, United States